HealthCor Management L.P. Buys 695,090 Shares of Boston Scientific Co. (BSX)
HealthCor Management L.P. increased its stake in Boston Scientific Co. (NYSE:BSX) by 98.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,402,950 shares of the medical equipment provider’s stock after purchasing an additional 695,090 shares during the quarter. Boston Scientific makes up approximately 1.8% of HealthCor Management L.P.’s investment portfolio, making the stock its 25th biggest position. HealthCor Management L.P. owned approximately 0.10% of Boston Scientific worth $54,014,000 as of its most recent filing with the SEC.
Other institutional investors also recently made changes to their positions in the company. Captrust Financial Advisors raised its holdings in Boston Scientific by 103.8% in the 2nd quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 1,594 shares during the period. Moody National Bank Trust Division bought a new position in Boston Scientific in the 3rd quarter worth $108,000. Capital Guardian Trust Co. bought a new position in Boston Scientific in the 3rd quarter worth $110,000. NumerixS Investment Technologies Inc raised its holdings in Boston Scientific by 1,650.0% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 3,500 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 3,300 shares during the period. Finally, Vantage Investment Advisors LLC raised its holdings in Boston Scientific by 82.4% in the 3rd quarter. Vantage Investment Advisors LLC now owns 2,989 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 1,350 shares during the period. 90.85% of the stock is currently owned by institutional investors.
A number of equities analysts recently commented on the company. UBS Group assumed coverage on Boston Scientific in a report on Tuesday, November 27th. They issued a “buy” rating and a $45.00 target price on the stock. Oppenheimer reaffirmed a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 21st. BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a report on Wednesday, November 21st. SunTrust Banks raised their target price on Boston Scientific to $44.00 and gave the stock a “buy” rating in a report on Tuesday, November 20th. Finally, Stephens reiterated a “market perform” rating and issued a $40.00 price target on shares of Boston Scientific in a research note on Monday, November 19th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twenty have given a buy rating and three have issued a strong buy rating to the stock. Boston Scientific has an average rating of “Buy” and an average price target of $39.54.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.34 by $0.01. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.40 billion. Boston Scientific had a return on equity of 26.44% and a net margin of 6.93%. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.31 earnings per share. Analysts expect that Boston Scientific Co. will post 1.39 EPS for the current year.
In other news, EVP Kevin J. Ballinger sold 37,430 shares of the firm’s stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $38.00, for a total transaction of $1,422,340.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Michael F. Mahoney sold 116,666 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $38.80, for a total value of $4,526,640.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 346,161 shares of company stock valued at $13,009,952. Company insiders own 0.73% of the company’s stock.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Story: What is a conference call?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.